This Company should worry more about capturing mar
Post# of 11802
(Total Views: 336)
Posted On: 02/29/2020 6:27:10 PM
This Company should worry more about capturing market share in the diabetic market. Leave the coronavirus to people with actual ability
Well if this advice was coming from THE consultant to the industry, instead of someone masquerading as an expert, the advice giver would know that it is easier to complete an impedance methodology straight up in 2020, where the measurement is taken by a much more sensitive instrument than existed in 1984, or even in 2013, where change in current is measured over a short period of time (Corona or Ebola) instead of creating a mixing of chemicals that creates a reaction in a known time period (say 5 seconds) that in turn changes the production of current (a glucose method). One type of method (glucose oxidase and glucose dehydroginase) was novel in 1984 and continues until today, primarily because the FDA stifles competition by erecting barriers for the entry of small companies, while the other impedance electrode methods, sees its first implementation in 2014 (Roche Aviva) and its second more aggressive implementation (Gen TBG) in 2020.
But then I am writing to someone claiming to be THE consultant to the industry, at least those companies that count --- which is a big joke because it is a suspension of disbelief that companies like Roche, Lifescan, Abbott and Bayer, The Big 4 who spend tens or hundereds of million of $$ competing with each other, would in one instance draw from the brilliance of one biotech consultant, unless, of course, all of these companies were looking to set up penny stock trading endeavors.
Like my friend Barbara Asbell has said the last 15 years, ... salesman should sell, stock traders should trade, message board posters should post (about things they actually know about), engineers and chemists should make things work, and managers should manage. People around here, especially faux experts, would be better off taking that advice. The people at DECN, including their EXPERTS in Korea and Pennsylvania are the real deal and do not and have not embellished or lied about their credentials on a message board, apparently solely for the purpose of acceptance. All IMO.
Well if this advice was coming from THE consultant to the industry, instead of someone masquerading as an expert, the advice giver would know that it is easier to complete an impedance methodology straight up in 2020, where the measurement is taken by a much more sensitive instrument than existed in 1984, or even in 2013, where change in current is measured over a short period of time (Corona or Ebola) instead of creating a mixing of chemicals that creates a reaction in a known time period (say 5 seconds) that in turn changes the production of current (a glucose method). One type of method (glucose oxidase and glucose dehydroginase) was novel in 1984 and continues until today, primarily because the FDA stifles competition by erecting barriers for the entry of small companies, while the other impedance electrode methods, sees its first implementation in 2014 (Roche Aviva) and its second more aggressive implementation (Gen TBG) in 2020.
But then I am writing to someone claiming to be THE consultant to the industry, at least those companies that count --- which is a big joke because it is a suspension of disbelief that companies like Roche, Lifescan, Abbott and Bayer, The Big 4 who spend tens or hundereds of million of $$ competing with each other, would in one instance draw from the brilliance of one biotech consultant, unless, of course, all of these companies were looking to set up penny stock trading endeavors.
Like my friend Barbara Asbell has said the last 15 years, ... salesman should sell, stock traders should trade, message board posters should post (about things they actually know about), engineers and chemists should make things work, and managers should manage. People around here, especially faux experts, would be better off taking that advice. The people at DECN, including their EXPERTS in Korea and Pennsylvania are the real deal and do not and have not embellished or lied about their credentials on a message board, apparently solely for the purpose of acceptance. All IMO.
(1)
(1)Decision Diagnostics Corp (DECN) Stock Research Links
Scroll down for more posts ▼